Cybin (HELP) Non-Current Assets (2021 - 2026)
Cybin's (HELP) quarterly Non-Current Assets came in at $66.6 million in Q1 2026, up 3.22% YoY from $64.6 million in Q1 2025, and down 0.85% on a QoQ basis from $67.2 million in Q4 2025.
Cybin (HELP) Non-Current Assets (2021 - 2026) Analysis & Trends
Cybin (HELP) has 6 years of Non-Current Assets data on file, last reported at $66.6 million in Q1 2026.
- Quarterly Non-Current Assets rose 3.22% year-over-year to $66.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.5 million (changed N/A YoY) and the FY2026 annual result came in at $66.6 million, up 3.41% from the prior year.
- Non-Current Assets fell to $66.6 million in Q1 2026, from $67.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $67.2 million in Q4 2025 to a low of $1.9 million in Q1 2023.
- A 5-year average of $49.8 million and a median of $61.3 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets declined 2.49% — and 2024, when it jumped 166.18%.
- Tracing HELP's Non-Current Assets over 5 years: stood at $22.5 million in 2022, then soared by 164.05% to $59.5 million in 2023, then climbed by 3.29% to $61.5 million in 2024, then increased by 9.37% to $67.2 million in 2025, then declined by 0.85% to $66.6 million in 2026.
- The last three Non-Current Assets figures came in at $66.6 million (Q1 2026), $67.2 million (Q4 2025), and $66.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 66.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.64 Mn |
| Dec 31, 2025 | 67.22 Mn |
| Sep 30, 2025 | 66.67 Mn |
| Jun 30, 2025 | 67.16 Mn |
| Mar 31, 2025 | 64.57 Mn |
| Dec 31, 2024 | 61.46 Mn |
| Sep 30, 2024 | 61.33 Mn |
| Jun 30, 2024 | 61.33 Mn |
| Mar 31, 2024 | 61.96 Mn |
| Dec 31, 2023 | 59.50 Mn |
| Sep 30, 2023 | 23.04 Mn |
| Jun 30, 2023 | 38.59 Mn |
| Feb 28, 2023 | 1.90 Mn |
| Dec 31, 2022 | 22.53 Mn |
| Sep 30, 2022 | 23.63 Mn |
| Dec 31, 2021 | 20.64 Mn |
| Sep 30, 2021 | 20.66 Mn |
| Jun 30, 2021 | 20.56 Mn |
| Mar 31, 2021 | 20.25 Mn |